Clinical Context Obesity affects over 650 million adults worldwide and is associated with numerous comorbidities including type 2 diabetes, cardiovascular…
Browsing: Therapeutics
Drug-class and individual-agent evidence: GLP-1 receptor agonists, SGLT2 inhibitors, and the major trials behind semaglutide, tirzepatide, and related therapies.
Clinical Context The relationship between obesity and cardiovascular disease has long been recognized, but proving that weight loss reduces cardiovascular…
Summary: In adults with overweight/obesity (BMI ≥27) and established atherosclerotic CVD, without diabetes, semaglutide 2.4 mg once weekly for median…
Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) with NYHA class II-IV symptoms, semaglutide 2.4 mg subcutaneous…
Summary: In adults with type 2 diabetes and chronic kidney disease on stable ACE inhibitor or ARB therapy, semaglutide 1.0…
Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) from pooled STEP-HFpEF trials, stratified by baseline NT-proBNP tertiles,…
Summary: In adults with type 2 diabetes (n=1,879) from SURPASS-2 Phase 3 trial, once-weekly tirzepatide (5, 10, or 15 mg)…
Summary: In adults from pooled SURPASS-1, -2, -3 trials (n=3,792), stratified by early-onset T2D (diagnosed <40 years) vs later-onset (≥40…
Summary: In overweight/obese adults with type 2 diabetes and NAFLD, combination semaglutide plus empagliflozin for 52 weeks produced significantly greater…
Summary: In 1,145 adults with obesity-related HFpEF (BMI ≥30, LVEF ≥45%, NYHA II-IV) pooled from STEP-HFpEF and STEP-HFpEF DM trials,…